Letícia Ferreira Alves

Letícia Ferreira Alves

Auto-generated profile, based on publicly available information

Letícia Ferreira Alves

Department of Structural and Functional Biology, University of Campinas (UNICAMP), Campinas, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2022 in Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
LKLarissa Akemi Kido
Larissa Akemi Kido
IRIsabela Maria Urra Rossetto
Isabela Maria Urra Rossetto
ABAndressa Mara Baseggio
Andressa Mara Baseggio
GCGabriela Bortolanca Chiarotto
Gabriela Bortolanca Chiarotto
LALetícia Ferreira Alves
Letícia Ferreira Alves
VCValéria Helena Alves Cagnon
Valéria Helena Alves Cagnon
Larissa Akemi Kido, Isabela Maria Urra Rossetto, Andressa Mara Baseggio, Gabriela Bortolanza Chiarotto, Letícia Ferreira Alves, Felipe Rabelo Santos, Celina de Almeida Lamas, Mário Roberto Maróstica Jr, Valéria Helena Alves Cagnon. J Cancer Prev 2022;27:182-91. https://doi.org/10.15430/JCP.2022.27.3.182


25 April 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
ACAmanda Cabral
Amanda Cabral
DCDarlan da Silva Cândido
Darlan da Silva Cândido
SMSandra Maria Monteiro
Sandra Maria Monteiro
FLFrancine Lemos
Francine Lemos
DSDavid Saitovitch
David Saitovitch
VCVerônica Coelho
Verônica Coelho
Background: Operational tolerance (OT) is a state of graft functional stability that occurs after at least 1 year of immunosuppressant withdrawal. MicroRNAs (microRNA) are small non-coding RNAs that downregulate messenger RNA/protein expression of innumerous molecules and are critical for homeostasis. We investigated whether OT in kidney transplantation displays a differential microRNA profile, which would suggest that microRNAs participate in Operational Tolerance mechanisms, and may reveal potential molecular pathways. Methods: We first compared serum microRNA in OT (n = 8) with chronic rejection (CR) (n = 5) and healthy individuals (HI) (n = 5), using a 768-microRNA qPCR-panel. We used the Thermo Fisher Cloud computing platform to compare the levels of microRNAs in the OT group in relation to the other study groups. We performed validation experiments for miR-885-5p, by q-PCR, in a larger number of study subjects (OT = 8, CR = 12, HI = 12), as individual samples. Results: We detected a differential microRNA profile in OT vs. its opposing clinical outcome—CR—suggesting that microRNAs may integrate transplantation tolerance mechanisms. Some miRNAs were detected at higher levels in OT: miR-885-5p, miR-331-3p, miR-27a-5p vs. CR; others, we found at lower levels: miR-1233-3p, miR-572, miR-638, miR-1260a. Considering highly predicted/experimentally demonstrated targets of these miRNAs, bioinformatics analysis revealed that the granzyme B, and death receptor pathways are dominant, suggesting that cell death regulation integrates transplantation tolerance mechanisms. We confirmed higher miR-885-5p levels in OT vs. CR, and vs. HI, in a larger number of subjects. Conclusions: We propose that epigenetics mechanisms involving microRNAs may integrate human transplantation tolerance mechanisms, and regulate key members of the cell death/survival signaling. miR-885-5p could favor cell survival in OT by diminishing the levels of CRADD/RAIDD and CASP3. Nonetheless, given the nature of any complex phenomenon in humans, only cumulative data will help to determine whether this microRNA differential profile may be related to the cause or consequence of operational tolerance.

31 August 2019 in Cell and tissue research
Verified
Journal Article
Closed access
PDF file
RSRaquel Frenedoso Da Silva
Raquel Frenedoso Da Silva
TBThais Petrochelli Banzato
Thais Petrochelli Banzato
LALetícia Ferreira Alves
Letícia Ferreira Alves
LGLivia Camara de Carvalho Galvão
Livia Camara de Carvalho Galvão
RARajesh Agarwal
Rajesh Agarwal
VCValéria Helena Alves Cagnon
Valéria Helena Alves Cagnon

13 September 2024 in WIREs RNA
Verified
Journal Article
Closed access
PDF file
CMCarolina Mathias
Carolina Mathias
ARAna Carolina Rodrigues
Ana Carolina Rodrigues
SBSuelen Cristina Soares Baal
Suelen Cristina Soares Baal
AAAlexandre Luiz Korte de Azevedo
Alexandre Luiz Korte de Azevedo
VKVanessa Nascimento Kozak
Vanessa Nascimento Kozak
Daniela GradiaDaniela Gradia
Daniela Gradia

31 May 2024 in Translational Oncology
Verified
Journal Article
Open access
LALetícia Ferreira Alves
Letícia Ferreira Alves
LMLeonardo Augusto Marson
Leonardo Augusto Marson
MSMicheli Severo Sielski
Micheli Severo Sielski
CVCristina Pontes Vicente
Cristina Pontes Vicente
EKEdna Teruko Kimura
Edna Teruko Kimura
MGMurilo Vieira Geraldo
Murilo Vieira Geraldo
Background: In previous studies, we demonstrated the downregulation of several miRNAs from the DLK1-DIO3 genomic region in papillary thyroid carcinoma (PTC). Due to the large number of miRNAs within this region, the individual contribution of these molecules to PTC development and progression remains unclear. Objective: In this study, we aimed to clarify the contribution of DLK1-DIO3-derived miRNAs to PTC. Methods: We used different computational approaches and in vitro resources to assess the biological processes and signaling pathways potentially modulated by these miRNAs. Results: Our analysis suggests that, out of more than 100 mature miRNAs originated from the DLK1-DIO3 region, a set of 12 miRNAs accounts for most of the impact on PTC development and progression, cooperating to modulate distinct cancer-relevant biological processes, such as cell migration, extracellular matrix remodeling, and signal transduction. The restoration of the expression of one of these miRNAs (miR-485–5p) in a BRAFT199A-positive PTC cell line impaired proliferation and migration, suppressing the expression of GAB2 and RAC1, validated miR-485–5p targets. Conclusions: Overall, our results shed light on the role of the DLK1-DIO3 region, which harbors promising tumor suppressor miRNAs in thyroid cancer, and open prospects for the functional exploration of these miRNAs as therapeutic targets for PTC.